Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,946 DKK | -0.99% | -3.09% | -9.70% |
06:38pm | Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance | MT |
04-30 | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.70% | 18.2B | |
-1.38% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.65% | 21.68B | |
-39.98% | 17.02B | |
-10.00% | 16.36B | |
+7.75% | 14.39B | |
+37.19% | 12.37B | |
+306.88% | 8.43B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating